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Introduction
Mutations in collagen X cause the short-limbed dwarfism 
metaphyseal chondrodysplasia type Schmid (MCDS) (1–3). 
Mutant collagen X proteins misfold and are retained within the 
ER of hypertrophic chondrocytes (4), causing an increase in ER 
stress and activation of the unfolded protein response (UPR), 
ultimately disrupting growth-plate hypertrophic cell differenti-
ation and bone growth (5, 6). Indeed, triggering increased ER 
stress by targeting the expression of an exogenous misfolding 
protein (cog form of thyroglobulin) to hypertrophic chondro-
cytes is sufficient to induce an MCDS-like phenotype, demon-
strating the central role of ER stress in the disease mechanism 
(6). The presence of increased ER stress in hypertrophic chon-
drocytes causes the cells to disengage their differentiation pro-
gram in an attempt to reduce ER stress and survive (5, 6). The 
altered differentiation program causes a decreased production 
of VEGF by hypertrophic chondrocytes, resulting in delayed 
vascular invasion and a characteristic expansion in the hyper-
trophic zone width (5, 6).
Carbamazepine (CBZ) is an FDA-approved drug for use in 
epilepsy, bipolar disorder, and neuropathic pain (7). CBZ also 
stimulates both autophagy and proteasomal degradation path-
ways and thereby has been shown to prevent liver fibrosis occur-
ring as a result of misfolded protein accumulation in a mouse 
model of α1-antitrypsin deficiency (8–10). Here, we show that 
CBZ is able to reduce ER stress caused by the intracellular accu-
mulation of MCDS-causing forms of collagen X by stimulating 
their intracellular degradation through autophagy or proteaso-
mal degradation, depending on the particular mutation. In vivo 
in an MCDS mouse model, which expresses the MCDS-causing 
N617K mutation in collagen X, CBZ induced a reduction in ER 
stress and enabled hypertrophic chondrocytes to improve their 
differentiation, resulting in increased bone growth rates and 
reduced skeletal dysplasia.
Results and Discussion
We hypothesized that drugs capable of reducing the ER stress 
caused by mutant forms of collagen X may be of use as poten-
tial treatments for MCDS. We therefore screened our MCDS 
cell culture model (HeLa cells transiently expressing the MCDS- 
causing N617K collagen X mutation) with a panel of compounds 
that act as chemical chaperones and/or relieve ER stress, includ-
ing sodium phenylbutyrate (11), CBZ (10), tauroursodeoxycho-
lic acid (11), glycerol (12), dimethyl suphoxide (13), verapamil 
(14), and quercetin (15). CBZ was the only compound tested that 
reduced the levels for each of the ER stress–induced mRNAs, 
BiP, CHOP, and spliced XBP1 (Supplemental Figure 1; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI93094DS1). Furthermore, CBZ was able to 
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mulated over a 24-hour period (Figure 1, F–I, and Supplemental 
Figure 2D). For N617K and G618V, intracellular accumulation 
was enhanced by the proteasomal — but not by the autophagy — 
inhibitor, which was added for the final 8 hours of culture (Figure 
1, F and G, and Supplemental Figure 2D). In contrast, the intra-
cellular accumulation of NC1del10 and Y598D was enhanced by 
the autophagy — but not the proteasomal — inhibitor (Figure 1, 
H and I, and Supplemental Figure 2D). CBZ treatment reduced 
the intracellular accumulation of each mutant protein without 
altering its degradation pathway (Figure 1, F–I, and Supplemen-
tal Figure 2D) or its secretion into the medium (data not shown). 
CBZ was therefore able to stimulate the degradation of mutant 
collagen X by both autophagy and ER-associated degradation via 
the proteasome. The different pathways by which N617K/G618V 
compared with NC1del10/Y598D mutations were degraded pre-
sumably relate to their abilities to be resolved from a misfolded 
aggregate to a single polypeptide chain, with the latter being 
significantly reduce the mRNA levels for these genes in cells 
expressing 4 different MCDS-causing collagen X mutations 
(N617K, Y598D, G618V, and NC1del10; ref. 4) (Figure 1, A–C). 
For each of these mutations, the CBZ-induced reduction in ER 
stress was accompanied by significant reductions in the levels of 
intracellularly retained mutant collagen X protein (Figure 1, D 
and E). Next, we focused on the rates of degradation to explain 
the CBZ-induced reduction in mutant protein accumulation, 
since the drug did not affect cell viability, collagen X mRNA 
levels, or rates of general protein synthesis (Supplemental Fig-
ure 2, A–C). CBZ is a known stimulator of autophagy via mTOR- 
independent mechanisms (8), but has also been shown to stimu-
late degradation via proteasomal mechanisms (9). We tested the 
effects of both proteasomal (proteasome inhibitor II [PSII]) and 
autophagy (chloroquine [CQ]) inhibitors on the accumulation of 
mutant collagen X in the cell culture system in the presence and 
absence of CBZ. In the absence of CBZ, mutant collagen X accu-
Figure 1. Effects of CBZ treatment on ER stress induced by 4 different MCDS-causing mutations in collagen X. (A) BiP, (B) CHOP, and (C) spliced XBP1 
(sXBP1) mRNA (relative to β actin mRNA) in cells transiently expressing 1 of 4 mutant collagen X constructs and treated for 24 hours with CBZ (20 μM). 
Mean ± SEM (n = 4). UTF, untransfected control. (D) Western blot of intracellular collagen X (Col X) protein levels with and without 24-hour CBZ treatment 
and (E) quantification of 3 independent experiments (mean ± SEM). (F–I) Quantification of 3 independent Western blot experiments for intracellular 
N617K, G618V, Nc1del10, and Y598D collagen X protein levels (75 kD) in the presence or absence of 20 μM CBZ for 24 hours (see Supplemental Figure 2D 
for representative blots). Inhibitors of the proteasome (PSII) or lysosome (CQ) were added at 16 hours after transfection for a further 8 hours. Collagen is 
expressed relative to its GAPDH level and was normalized to the retained collagen X level at the 16-hour untreated time point. Mean ± SEM. *P < 0.05;  
**P < 0.005; ***P < 0.0005. All statistical analyses by ANOVA.
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treatment period (Supplemental Figure 4). These data show that 
CBZ treatment is capable of reducing MCDS pathology, since 
it is already established that the degree of hypertrophic zone 
expansion positively correlates with disease severity (5, 6). CBZ 
treatment of WT mice had no effect on hypertrophic zone width 
(Supplemental Figure 5, A and B).
Immunohistochemical analysis of tibial growth plates 
revealed, as expected, that WT collagen X was secreted into the 
extracellular matrix surrounding the hypertrophic chondro-
cyte, whereas in MCDS mice, the mutant protein was retained 
intracellularly with delayed and reduced collagen X secretion 
in the lower half of the hypertrophic zone (Figure 2B) (6). The 
CBZ-induced degradation of misfolded protein described 
above accounts for the reduced level of intracellular collagen 
X with no overt increase in secreted collagen X observed in the 
CBZ-treated MCDS mice (Figure 2C and Supplemental Figure 
4). CBZ had no effect on collagen X protein localization in WT 
mice (Supplemental Figure 5C). MCDS mice displayed a sig-
degraded via the proteasome and the aggregated forms of colla-
gen by autophagy as described previously (16).
In order to examine the effects of CBZ in vivo, we treated 
MCDS mice with CBZ (250 mg/kg body weight/d) for 1 to 3 
weeks. This dose level of CBZ in mice is equivalent to that rou-
tinely used in children to treat epilepsy and related disorders 
when species differences in drug dosage levels are taken into 
account (17). Mice dosed by gavage achieved a serum CBZ con-
centration of 4.4 μg/ml 2 hours after ingestion. Newborn MCDS 
pups treated from E10 by gavaging the pregnant dams displayed 
a 40% reduction in the expansion of the growth plate width seen 
in the untreated MCDS pups (P = 0.0001; Supplemental Figure 
3). Untreated 3-week-old MCDS mice displayed the character-
istic expansion in the width of the hypertrophic zone compared 
with WT mice. One week of CBZ treatment was sufficient to 
cause a significant reduction in the width of the hypertrophic 
zone compared with that in untreated MCDS controls (Figure 
2, A and D), and this effect continued throughout the 3-week 
Figure 2. Effect of CBZ on the growth plate pathology associated with MCDS. Three-week-old MCDS mice were treated with CBZ for a period of 1 week. 
Untreated MCDS mice and mice WT for collagen X were used as controls. (A) H&E staining of the tibial growth plate and immunohistochemistry for (B) 
collagen X and (C) Bip/Grp78. Brackets indicate the hypertrophic zone. Scale bars: 100 μM. (D) Hypertrophic zone measurements at 4 weeks of age. Mean 
± SEM. MCDS vs MCDS CBZ *P < 0.05. (E) Typical Western blots of rib growth plate cartilage extracts at 4 weeks of age for Bip and Atf4 alongside their 
Coomassie blue–stained protein loading control gel (F). (G and H) Quantification of BiP and Atf4 (n = 3 independent analyses). (I) X-ray images of pelvis 
illustrating the distortion of the ischial tuberosity in MCDS mice at 6 weeks of age. (J) The angle between the lines was measured for each group (mean ± 
SEM, n = 5). Bone growth expressed as percentage of increase based on length at 3 weeks of age in each animal for (K) tibia and (L) femur. Mean ± SEM.  
n = 6 MCDS mice and n = 7 MCDS CBZ-treated mice. *P < 0.05; **P < 0.005; ***P < 0.0005. All statistical analyses by ANOVA.
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a disrupted pattern of collagen X gene expression, particularly 
in the lower half of the hypertrophic zone (Figure 3A), accompa-
nied by a sporadic reexpression of collagen II mRNA (Figure 3B). 
CBZ treatment of MCDS mice reduced the disruption of colla-
gen X and collagen II mRNA expression in the hypertrophic zone 
(Figure 3, A and B). In WT mice, the Opn and Mmp13 mRNAs are 
expressed in a coordinated fashion by the terminal hypertrophic 
chondrocytes immediately adjacent to the vascular invasion 
front, whereas in MCDS mice, coordination of differentiation is 
lost and cells autonomously express these terminal markers in 
the lower half of the expanded hypertrophic zone (Figure 3, C 
and D) (5, 6). CBZ treatment of MCDS mice caused Opn gene 
expression to become more focused at or close to the vascular 
invasion front (Figure 3C) and made Mmp13 gene expression 
indistinguishable from that of the WT controls (Figure 3D). In 
addition, CBZ treatment of MCDS mice not only partially cor-
rected the reduced osteoclast recruitment to the vascular inva-
sion front (Figure 3, E and F), but also improved cell hypertrophy, 
based on the height of the terminal hypertrophic chondrocytes 
(Figure 3G) (5, 6). These data clearly indicate that CBZ treatment 
improves the disrupted hypertrophic differentiation apparent in 
MCDS mice. The lack of effect in WT mice shows CBZ does not 
have obvious effects on normal physiological processes, as is also 
suggested by its long and successful clinical use for the treatment 
of other unrelated disorders.
In summary, CBZ treatment stimulates the degradation of 
intracellularly retained MCDS-causing mutant forms of collagen X 
by either autophagy or proteasomal pathways, depending upon the 
nature of the particular mutation, reducing the level of ER stress both 
in vitro and in vivo. The CBZ-induced reduction in ER stress causes 
nificant increase in immunostaining for Bip (Figure 2C) and in 
the protein levels of both Bip and Atf4 in growth-plate extracts 
(Figure 2E), clearly indicating elevated ER stress. CBZ treat-
ment reduced Bip immunostaining in growth plates of MCDS 
mice (Figure 2C) and significantly reduced the levels of both 
Bip and Atf4 on Western blots (Figure 2, E–H). Therefore, CBZ 
treatment appears to reduce ER stress in the growth plate of 
MCDS mice by directly stimulating the proteolysis of mutant 
collagen X accumulating in the hypertrophic chondrocytes of 
MCDS mice.
One feature of the MCDS pathology in mice is the presence 
of hip dysplasia — characterized by an increase in the angle of 
deflection of the ischial tuberosity (6). Six-week-old WT mice 
had an average deflection of 7.7° compared with 31.6° in the 
untreated MCDS mice (Figure 2, I and J). CBZ treatment for 3 
weeks reduced this deflection to 25.4°, illustrating that relatively 
short periods of CBZ treatment have the capacity to improve 
MCDS-associated skeletal dysplasia (Figure 2, I and J). In addi-
tion, 3 weeks of CBZ treatment resulted in significant increases 
in the rates of long bone growth (Figure 2, K and L). Three 
weeks of CBZ treatment promoted 1.25- and 1.44-fold increas-
es in the lengths of tibial and femur bone growth, respectively, 
in MCDS mice (Figure 2, H and I; mean ± SEM [% increase in 
bone length over treatment period], tibia: untreated 25.6 ± 1.3 
[n = 6] vs. CBZ 32.7 ± 1.6 [n = 7] P < 0.05; femur: untreated 27.8 
± 2.3 [n = 6] vs. CBZ 40.1 ± 2.0 [n = 7], P < 0.05). CBZ treatment 
did not cause a significant increase in bone growth rates in WT 
mice (Supplemental Figure 4, D and E).
The altered differentiation of hypertrophic chondrocytes 
caused by increased ER stress in MCDS (5, 6) is characterized by 
Figure 3. Effect of CBZ on chondrocyte differentiation. MCDS mice were treated with CBZ for 1 week. In situ hybridization for (A) collagen X (Col10a1) 
mRNA, (B) collagen II (Col2a1) mRNA, (C) Opn mRNA (arrows), and (D) Mmp13 mRNA (arrows). (E) TRAP staining for osteoclasts (arrows). (F) Number of 
osteoclasts per mm of vascular invasion front. Mean ± SEM (n = 4). (G) Final height attained by hypertrophic chondrocytes adjacent to vascular invasion 
front. Scale bars: 100 μM. Mean ± SEM (n = 5). *P < 0.05; **P < 0.005; ***P < 0.0005. All statistical analyses by ANOVA. Yellow brackets show hypertro-
phic zone; dashed lines show vascular invasion front.
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less disruption to the differentiation process in hypertrophic chon-
drocytes, leading to decreased skeletal dysplasia and increased bone 
growth rates. These data provide evidence for the CBZ-induced stim-
ulation of intracellular proteolysis being a potential treatment strate-
gy for reducing the clinical severity of MCDS, and based on the data 
presented herein, the drug has recently been licensed by the Europe-
an Medicines Agency for this purpose (http://www.ema.europa.eu/
ema/index.jsp?curl = pages/medicines/human/orphans/2016/11/
human_orphan_001864.jsp&mid = WC0b01ac058001d12b). CBZ 
has the potential to act as a therapeutic agent for a broad range of 
human connective tissue diseases that involve ER stress resulting 
from the intracellular accumulation of a mutant structural protein.
Methods
Statistics. Multiple comparisons were performed by 1-way ANOVA 
using GraphPad Prism 6.0 software. A P value of less than 0.05 was 
considered significant.
Study approval. The animal experiments performed in this study 
were approved by the University of Manchester Animal Welfare and 
Ethical Review Body. Animals were maintained, handled, and sacrificed 
in strict accordance with United Kingdom Home Office regulations.
See Supplemental Methods for additional information.
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